A trial looking at erdafitinib and cetrelimab for bladder cancer (SOGUG-NEOWIN)

This trial is looking at erdafitinib on its own or in combination with cetrelimab for bladder cancer that has spread into or through the muscle layer of the bladder. This is called muscle invasive bladder cancer.

It is open to people with muscle invasive bladder cancer that are not able to or do not want to have cisplatin.

You pronounce erdafitinib as eer-da-fit-i-nib.

You pronounce cetrelimab as set-re-li-mab.